Law360, New York (March 05, 2007, 12:00 AM ET) -- After years of warring over Wellbutrin, Canadian pharmaceutical company Biovail Corp. has thrown in the towel and agreed to a “comprehensive” settlement with a slew of drugmakers seeking to launch a generic version of the blockbuster antidepressant.
On Monday, Biovail revealed that it had reached an agreement with Anchen Pharmaceuticals LLP, Impax Laboratories Inc., Watson Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. in its long-standing battle over Wellbutrin XL.
Biovail had begun legal proceedings against the companies in 2005 after they filed abbreviated new drug applications...
Biovail Abandons Wellbutrin Litigation
To view the full article, take a free trial now.
